

Unless otherwise defined, terms and expressions used in this announcement shall have the same meanings as those defined in the prospectus (the “**Prospectus**”) of Mediwelcome Healthcare Management & Technology Inc. (the “**Company**”) dated December 31, 2020.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered. Any investment decision in relation to the Global Offering should be taken solely in reliance on the information provided in the Prospectus.

In connection with the Global Offering, CEB International Capital Corporation Limited as stabilizing manager (the “**Stabilizing Manager**”), or any person acting for it, on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail in the open market for a limited period commencing on the Listing Date. However, there is no obligation on the Stabilizing Manager, or any person acting for it, to conduct any such stabilizing action. Such stabilizing action, if taken, will be conducted at the absolute discretion of the Stabilizing Manager or any person acting for it, and may be discontinued at any time. Any such stabilization activity is required to be brought to an end within 30 days of the last day for lodging applications under the Hong Kong Public Offering, being February 7, 2021. Such stabilization action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on February 7, 2021, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken to support the price of the Shares. Demand for the Shares, and therefore the price of the Shares, could fall.



## Mediwelcome Healthcare Management & Technology Inc.

麥迪衛康健康醫療管理科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

### GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 50,000,000 Shares (subject to adjustment and the Over-allotment Option)
Number of Hong Kong Offer Shares	: 5,000,000 Shares (subject to adjustment)
Number of International Offer Shares	: 45,000,000 Shares (subject to adjustment and the Over-allotment Option)
Offer Price	: Not more than HK\$4.00 per Offer Share and expected to be not less than HK\$3.00 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal Value	: HK\$0.00001 per Share
Stock Code	: 2159

*Sole Sponsor and Sole Global Coordinator*



*Joint Bookrunners*



The Company has applied to the Listing Committee of the Stock Exchange for the grant of listing of, and permission to deal in, the Shares in issue and to be issued as described in the Prospectus (including any Shares which may be issued pursuant to the exercise of the Over-allotment Option and any Shares to be issued upon the exercise of any options which may be granted under the Share Option Scheme). Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Tuesday, January 19, 2021, dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. in Hong Kong on Tuesday, January 19, 2021. In the event the Over-allotment Option is exercised, an announcement will be made by the Company which will be posted on the website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and on the website of the Company ([www.mediwelcome.com](http://www.mediwelcome.com)).

The Global Offering comprises the Hong Kong Public Offering of initially 5,000,000 Shares (subject to adjustment) representing 10% of the total number of Offer Shares initially available under the Global Offering, and the International Offering of initially 45,000,000 Shares (subject to adjustment and the Over-allotment Option) representing 90% of the total number of Offer Shares initially available under the Global Offering. The Global Offering represents 25% of the issued share capital of the Company upon completion of the Global Offering (assuming the Over-allotment Option is not exercised), on and subject to the terms and conditions as set out in the Underwriting Agreements and the Prospectus. The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus. In particular, the Sole Global Coordinator may at its discretion reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, then up to 5,000,000 Offer Shares may be reallocated to the Hong Kong Public Offering from the International Offering, so that the total number of the Offer Shares available under the Hong Kong Public Offering will be increased to 10,000,000 Offer Shares, representing 20% of the total number of the Offer Shares initially available under the Global Offering, and the final Offer Price shall be fixed at the bottom end of the Offer Price range (i.e. HK\$3.00 per Offer Share) stated in the Prospectus. For details, please refer to the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus.

Under the International Underwriting Agreement, the Company is expected to grant to the International Underwriters, exercisable by the Sole Global Coordinator (for itself and on behalf of the International Underwriters), the Over-allotment Option, at any time from the Listing Date until 30 days after the last day for lodging applications under the Hong Kong Public Offering (the last day for exercise of the Over-allotment Option being Sunday, February 7, 2021) to require the Company to issue up to an aggregate of 7,500,000 Shares, representing 15% of the Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering, to cover over-allocations in the International Offering, if any.

Subject to the granting of the approval for listing of, and permission to deal in, the Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Stock Exchange. For such other date as may be determined by HKSCC, the settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second business day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

The Offer Price will not be more than HK\$4.00 per Offer Share and is currently expected to be not less than HK\$3.00 per Offer Share, unless otherwise announced. Applicants for the Hong Kong Offer Shares are required to pay, on application, the maximum Offer Price of HK\$4.00 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price, as finally determined on the Price

Determination Date, is lower than HK\$4.00 per Offer Share (excluding brokerage fee, SFC transaction levy and Stock Exchange trading fee thereon), or if the conditions of the Hong Kong Public Offering are not fulfilled in accordance with the section headed “Structure of the Global Offering – Conditions of the Global Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage fee, SFC transaction levy and Stock Exchange trading fee will be refunded, without interest or cheque or banker’s cashier will not be cleared. Please refer to “How to Apply for Hong Kong Offer Shares – 13. Refund of Application Monies” in the Prospectus. The Price Determination Date is expected to be on or around Friday, January 8, 2021. If, for any reason, the Offer Price is not agreed on or before Monday, January 11, 2021 between the Company and the Sole Global Coordinator (for itself and on behalf of the Underwriters), the Global Offering will not proceed and will lapse accordingly. In such event, the Company will issue an announcement to be published on the website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the website of the Company ([www.mediwelcome.com](http://www.mediwelcome.com)).

**Applications for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the relevant Application Forms, and the designated website ([www.eipo.com.hk](http://www.eipo.com.hk)) for White Form eIPO.**

Applicants who wish to have the Hong Kong Offer Shares issued in their own names should (i) complete and sign the **WHITE** Application Form; or (ii) submit applications online through the designated website of the **White Form eIPO** Service Provider at [www.eipo.com.hk](http://www.eipo.com.hk) under the **White Form eIPO** service. Applicants who wish to have the Hong Kong Offer Shares issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants should (i) complete and sign the **YELLOW** Application Form; or (ii) give electronic application instructions to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Thursday, December 31, 2020 till 12:00 noon on Friday, January 8, 2021 (or such later date as may apply as described in the section headed “How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists” in the Prospectus) from the following addresses of the Hong Kong Underwriters:

**CEB International Capital Corporation Limited**

22/F, AIA Central  
1 Connaught Road Central  
Central, Hong Kong

**Aristo Securities Limited**

Room 101, 1st Floor  
On Hong Commercial Building  
145 Hennessy Road  
Wanchai, Hong Kong

**BOCOM International Securities Limited**

15/F Man Yee Building  
68 Des Voeux Road Central  
Hong Kong

**CMBC Securities Company Limited**

45/F, One Exchange Square  
8 Connaught Place  
Central, Hong Kong

**Ruibang Securities Limited**

9/F Sang Woo Building  
227-228 Gloucester Road  
Wanchai, Hong Kong

**SPDB International Capital Limited**

33/F, SPD Bank Tower  
One Hennessy  
1 Hennessy Road  
Hong Kong

**Wonderland International Securities Limited**

26/F Tung Hip Commercial Building  
252 Des Voeux Road Central  
Hong Kong

or any of the following designated branches of the receiving bank of the Hong Kong Public Offering:

**Bank of China (Hong Kong) Limited**

<b>District</b>	<b>Branch Name</b>	<b>Address</b>
<b>Hong Kong Island</b>	Bank of China Tower Branch	1 Garden Road, Hong Kong
<b>Kowloon</b>	Yau Ma Tei Branch	471 Nathan Road, Yau Ma Tei, Kowloon
<b>New Territories</b>	Metro City Branch	Shop 209, Level 2, Metro City Phase 1, Tseung Kwan O, New Territories

Copies of the Prospectus, together with the **YELLOW** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Thursday, December 31, 2020 till 12:00 noon on Friday, January 8, 2021 from the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or from your stockbroker.

The **WHITE** or **YELLOW** Application Form completed in accordance with the instructions printed thereon, together with a cheque or banker's cashier order attached and marked payable to "**BANK OF CHINA (HONG KONG) NOMINEES LIMITED – MEDIWELCOME HEALTHCARE PUBLIC OFFER**" should be deposited in the special collection boxes provided at any of the designated branches of the receiving bank referred to above on such dates and during such time as specified in the Application Forms.

Your **WHITE** or **YELLOW** Application Form can be lodged at the following times on the following dates:

Thursday, December 31, 2020	–	9:00 a.m. to 4:00 p.m.
Saturday, January 2, 2021	–	9:00 a.m. to 12:00 noon
Monday, January 4, 2021	–	9:00 a.m. to 4:00 p.m.
Tuesday, January 5, 2021	–	9:00 a.m. to 4:00 p.m.
Wednesday, January 6, 2021	–	9:00 a.m. to 4:00 p.m.
Thursday, January 7, 2021	–	9:00 a.m. to 4:00 p.m.
Friday, January 8, 2021	–	9:00 a.m. to 12:00 noon

Applicants may apply online through the **White Form eIPO** service by submitting an application through designated website at [www.eipo.com.hk](http://www.eipo.com.hk) (24 hours daily, except on the last day for applications) from 9:00 a.m. on Thursday, December 31, 2020 till 11:30 a.m. on Friday, January 8, 2021 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Friday, January 8, 2021 or such later date as described in the section headed “How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists” in the Prospectus.

**The application for the Hong Kong Public Offering will commence on Thursday, December 31, 2020 until Friday, January 8, 2021. However, our Shares will not commence trading on the Stock Exchange until the Listing Date, which is expected to be on Tuesday, January 19, 2021. Such time period is longer than the normal market practice. The application monies (including brokerage, SFC transaction levy and Stock Exchange trading fee) will be held by the receiving bank on behalf of our Company and the refund monies, if any, will be returned to the applicants without interest on Monday, January 18, 2021. In addition, our Shares will not commence trading on the Stock Exchange until they are delivered, which is expected to be longer than the normal market practice but in any event not more than seven business days after the Price Determination Date. Investors should be aware that the dealings in Shares on the Stock Exchange are expected to commence on Tuesday, January 19, 2021.**

CCASS Clearing/Custodian Participants can input electronic application instructions at the following times on the following dates<sup>(1)</sup>:

Thursday, December 31, 2020	–	9:00 a.m. to 8:30 p.m.
Saturday, January 2, 2021	–	8:00 a.m. to 1:00 p.m.
Monday, January 4, 2021	–	8:00 a.m. to 8:30 p.m.
Tuesday, January 5, 2021	–	8:00 a.m. to 8:30 p.m.
Wednesday, January 6, 2021	–	8:00 a.m. to 8:30 p.m.
Thursday, January 7, 2021	–	8:00 a.m. to 8:30 p.m.
Friday, January 8, 2021	–	8:00 a.m. to 12:00 noon

*Note:*

- (1) The times in this sub-section are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants and/or Investor Participants.

CCASS Investor Participants can input electronic application instructions from 9:00 a.m. on Thursday, December 31, 2020 until 12:00 noon on Friday, January 8, 2021 (24 hours daily, except on Friday, January 8, 2021, the last application day).

The latest time for inputting your electronic application instructions will be 12:00 noon on Friday, January 8, 2021, the last day for applications or such later time as described in the section headed “How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists” in the Prospectus.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to announce the final Offer Price, the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on or before Monday, January 18, 2021 on the website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the website of the Company ([www.mediwelcome.com](http://www.mediwelcome.com)).

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be available at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares – 11. Publication of Results” in the Prospectus.

No temporary documents of title will be issued in respect of the Shares. No receipt will be issued for sums paid on application. Share certificates will only become valid at 8:00 a.m. in Hong Kong on Tuesday, January 19, 2021, provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised. Dealings in the Shares are expected to commence at 9:00 a.m. in Hong Kong on Tuesday, January 19, 2021. The Shares will be traded in board lots of 800 Shares each. The stock code of the Shares is 2159.

By order of the Board  
**Mediwelcome Healthcare Management & Technology Inc.**  
**Shi Wei**  
*Chairman and executive Director*

Hong Kong, Thursday, December 31, 2020

*As at the date of this announcement, the board of Directors of the Company comprises Mr. Shi Wei, Mr. Yang Weimin, Mr. Wang Liang, Mr. He Jiyong, Mr. Wang Wei and Mr. Sui Huijun as executive Directors; Ms. Zhang Yitao and Mr. Liu Xia as non-executive Directors; and Mr. Song Ruilin, Mr. Fei John Xiang, Mr. David Zheng Wang and Mr. Yang Xiaoxi as independent non-executive Directors.*